MRD Receives Support as a Biomarker for FDA Accelerated Approval in Myeloma Therapies | Blood Cancers Today
The FDA ODAC voted in favor of the use of MRD-negativity as an intermediate endpoint for accelerated approval in MM trials.
The FDA ODAC voted in favor of the use of MRD-negativity as an intermediate endpoint for accelerated approval in MM trials.
AbstractBackgroundCombination therapy with immune checkpoint inhibitors (ICIs) and vascular endothelial growth factor inhibitors (VEGFIs) has improved cancer outcomes and is increasingly used. Thes…
The ARASENS study analyzed the efficacy of darolutamide in combination with ADT and docetaxel for the treatment of mHSPC.
Welcome to the 33rd case of the Skeleton Key Group, a team of nephrologists from around the world who build a periodic education package for…
Prefibrotic myelofibrosis is the focus of “SOHO State of the Art Updates and Next Questions.”
An Education Session during ASCO24 will help oncologists foster deeper understanding of the needs of patients and caregivers, especially those from historically marginalized communities.
As part of infrastructure enhancements to ACC-related systems and platforms, the ability to log-in to JACC.org using ACC usernames and passwords will be unavailable from…
TCTMD: the most comprehensive online resource for interventional cardiology and beyond, with news coverage spanning the entire field of cardiovascular disease.
Welcome to the 33rd case of the Skeleton Key Group, a team of nephrologists from around the world who build a periodic education package for…
Hosted by Chadi Nabhan, MD, the inaugural HemOnc Pulse Live will address unanswered questions in hematologic malignancies May 3-4 in Chicago.